Matt Kapusta, uniQure CEO
UniQure stock doubles on FDA 'alignment' over accelerated approval for Huntington's drug
Dutch-based uniQure saw its stock $QURE rise by more than 120% on Tuesday after it disclosed that it is “in alignment” with the FDA on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
